



Prevalence of Antibiotic Resistance Genes among Human Gut-Derived Bifidobacteria

Sabrina Duranti,^a Gabriele Andrea Lugli,^a Leonardo Mancabelli,^a
Francesca Turrone,^a Christian Milani,^a Marta Mangifesta,^b Chiara Ferrario,^a
Rosaria Anzalone,^a Alice Viappiani,^b Douwe van Sinderen,^c Marco Ventura^a

Laboratory of Probiogenomics, Department of Life Sciences, University of Parma, Parma, Italy^a; GenProbio srl, Parma, Italy^b; APC Microbiome Institute and School of Microbiology, National University of Ireland, Cork, Ireland^c

ABSTRACT The microbiota of the human gastrointestinal tract (GIT) may regularly be exposed to antibiotics, which are used to prevent and treat infectious diseases caused by bacteria and fungi. Bacterial communities of the gut retain a reservoir of antibiotic resistance (AR) genes, and antibiotic therapy thus positively selects for those microorganisms that harbor such genetic features, causing microbiota modulation. During the first months following birth, bifidobacteria represent some of the most dominant components of the human gut microbiota, although little is known about their AR gene complement (or resistome). In the current study, we assessed the resistome of the *Bifidobacterium* genus based on phenotypic and genotypic data of members that represent all currently recognized bifidobacterial (sub)species. Moreover, a comparison between the bifidobacterial resistome and gut metagenome data sets from adults and infants shows that the bifidobacterial community present at the first week following birth possesses a reduced AR arsenal compared to that present in the infant bifidobacterial population in subsequent weeks of the first year of life. Our findings reinforce the concept that the early infant gut microbiota is more susceptible to disturbances by antibiotic treatment than the gut microbiota developed at a later life stage.

IMPORTANCE The spread of resistance to antibiotics among bacterial communities has represented a major concern since their discovery in the last century. The risk of genetic transfer of resistance genes between microorganisms has been extensively investigated due to its relevance to human health. In contrast, there is only limited information available on antibiotic resistance among human gut commensal microorganisms such as bifidobacteria, which are widely exploited by the food industry as health-promoting microorganisms or probiotic ingredients. In the current study, we explored the occurrence of antibiotic resistance genes in the genomes of bifidobacteria and evaluated their genetic mobility to other human gut commensal microorganisms.

KEYWORDS gut microbiomes, bifidobacteria, human gut, antibiotic resistance genes, resistomes

The human gut microbiota plays an important role in health and disease of the host through its impact on immunology, nutrition, and pathogenesis (1, 2). The microbiota may regularly be exposed to a variety of antimicrobial agents, such as antibiotics, which are used in the treatment and prevention of bacterial infection in human and veterinary medicine (3). Antibiotic therapy may cause secondary effects such as distortion of the homeostasis of microbial gut consortia (4) and selection for antibiotic-resistant microorganisms. In fact, bacteria have counteracted the action of antibiotics

Received 19 October 2016 **Accepted** 17 November 2016

Accepted manuscript posted online 18 November 2016

Citation Duranti S, Lugli GA, Mancabelli L, Turrone F, Milani C, Mangifesta M, Ferrario C, Anzalone R, Viappiani A, van Sinderen D, Ventura M. 2017. Prevalence of antibiotic resistance genes among human gut-derived bifidobacteria. *Appl Environ Microbiol* 83: e02894-16. <https://doi.org/10.1128/AEM.02894-16>.

Editor Harold L. Drake, University of Bayreuth

Copyright © 2017 American Society for Microbiology. All Rights Reserved.

Address correspondence to Marco Ventura, marco.ventura@unipr.it.

S.D. and G.A.L. contributed equally to this article.

through the acquisition of a specific genetic arsenal, also known as the resistome, which is involved in inactivation and/or removal of antibiotics. A large part of the resistome is contained within chromosomal DNA, although it may also be present on extrachromosomal replicons like plasmids and phages, which are transmissible to other members of the gut microbiota through horizontal gene transfer (HGT) events (5). Furthermore, antibiotic resistance may also be provided by a mutation in a gene encoding the antibiotic target, in which case the acquired resistance is not considered to be horizontally transferable (5). Antibiotic treatment selects for antimicrobial-resistant bacteria, where this selection is positively correlated with antibiotic usage (6). Furthermore, antibiotic resistance (AR) genes in gut commensal microorganisms are considered to be undesirable as they may lead to antibiotic resistance in human pathogens. Using HGT mechanisms, AR genes not only may be exchanged among members of the indigenous gut microbiota but also may be transferred to other bacteria that are just passing through the gastrointestinal tract (GIT), including several diet-associated bacteria (7). These studies have prompted the European Food Safety Authority (EFSA) to issue guidelines on the safety assessment of microorganisms used in food and feed production.

Bifidobacteria are common human gut microbiota members and are especially abundant during the first months following birth (2). Antibiotic therapy is commonly used to treat microbial infections in both infants and pregnant mothers and for antibiotic prophylaxis in preterm infants (8). Notably, infants without any exposure to antibiotics showed a higher percentage of *Bifidobacteriaceae* (8, 9). Thus, the occurrence of AR genes in bifidobacteria may increase their ecological fitness for gut persistence and colonization (10). Recently, the pan-genome, i.e., the full complement of genes of the *Bifidobacterium* genus has been reconstructed (11, 12), thereby providing a genomic data set, which will be important to identify the bifidobacterial resistome. Furthermore, we have evaluated the presence of AR genes in different strains belonging to the bifidobacterial (sub)species that are components of the qualified presumption of safety (QPS) list in accordance with the EFSA, such as *Bifidobacterium bifidum*, *Bifidobacterium breve*, *Bifidobacterium adolescentis*, *Bifidobacterium longum* subsp. *longum*, and *Bifidobacterium animalis* spp. (13, 14).

In the current study, we reconstructed the resistome of the *Bifidobacterium* genus based on both phenotypic and genotypic data, which together with the prediction of its genetic mobility allowed us to assess the potential of bifidobacterial AR genes to spread to the genomes of other gut bacteria. Furthermore, comparison of the, here identified, bifidobacterial resistome with those embedded in various microbiome data sets from infants and adults provides insights into the contribution of bifidobacteria to overall antibiotic resistance in the human gut microbial ecosystem.

RESULTS AND DISCUSSION

Assessment of antimicrobial susceptibility of bifidobacteria. The susceptibility toward eight different antibiotics, i.e., ampicillin, vancomycin, gentamicin, streptomycin, erythromycin, tetracycline, chloramphenicol, and clindamycin, representing those indicated by EFSA (15, 51), was determined for 91 *Bifidobacterium* strains (Fig. 1 and Tables 1 and 2). As displayed in Fig. 1 and Table 1, we determined the breakpoint values for each antibiotic for the type strain of each of the currently known 54 bifidobacterial (sub)species. All type strains belonging to the 54 (sub)species of the *Bifidobacterium* genus showed a unimodal breakpoint value distribution for ampicillin (<0.03 to 2 $\mu\text{g/ml}$), vancomycin (0.25 to 1 $\mu\text{g/ml}$), gentamicin (8 to 512 $\mu\text{g/ml}$), and chloramphenicol (0.5 to 2 $\mu\text{g/ml}$) (Fig. 1a, b, e, and g). In contrast, for erythromycin, clindamycin, streptomycin, and tetracycline, a bimodal distribution with two or three different subpopulations (Fig. 1c, d, f, and h) was observed. In addition, we evaluated the susceptibility toward the same set of antibiotics at the intraspecies level (Table 2). Such analyses are crucial in order to understand the variability of antibiotic resistance within a particular taxon and to provide scientific support for the EFSA-suggested breakpoint values. Remarkably, the breakpoint values put forward by EFSA for the genus *Bifido-*




FIG 1 Microbiological breakpoint values. Distribution of breakpoint values for ampicillin (a), vancomycin (b), erythromycin (c), clindamycin (d), gentamicin (e) streptomycin (f), chloramphenicol (g), and tetracycline (h) in all type strains of the 54 (sub)species belonging to the *Bifidobacterium* genus. All bar plots report the antibiotic concentration values on the x axis (micrograms per milliliter) with the y axis showing the percentage of strains. The vertical black line represents the EFSA breakpoint value.

bacterium are based on values that were determined for a very small number of strains or for just a single strain (although proposed to apply to the whole genus) (15). Our analyses highlight a unimodal distribution of antibiotic resistance toward ampicillin, vancomycin, gentamicin, erythromycin, clindamycin, and chloramphenicol for all bifi-

TABLE 1 Antibiotic sensitivity of all type strains belonging to the *Bifidobacterium* genus

Species	Resistance data ($\mu\text{g/ml}$) for:							
	Ampicillin	Vancomycin	Gentamicin	Streptomycin	Erythromycin	Clindamycin	Tetracycline	Chloramphenicol
<i>B. actinocoloniiforme</i> DSM 22766	0.0625	0.5	8	4	0.03	0.03	2	0.5
<i>B. adolescentis</i> ATCC 15703	0.0625	0.5	128	32	0.0625	0.03	1	1
<i>B. aesculapii</i> MRM 3/1	0.0625	0.5	64	16	0.0625	<0.03	8	0.5
<i>B. angulatum</i> LMG 11039	0.125	0.5	128	64	0.03	0.03	0.25	0.5
<i>B. animalis</i> subsp. <i>animalis</i> LMG 10508	0.125	0.5	64	32	0.25	4	1	2
<i>B. animalis</i> subsp. <i>lactis</i> DSM 10140	0.125	0.5	128	64	0.25	4	8	2
<i>B. asteroides</i> LMG 10735 (PRL2011)	0.0625	0.5	16	32	0.0625	0.0625	1	2
<i>B. biavatii</i> DSM 23969	0.125	0.5	32	8	0.0625	0.03	0.25	0.5
<i>B. bifidum</i> LMG 11041	<0.06	0.25	8	8	0.125	<0.06	0.5	0.5
<i>B. bohemicum</i> DSM 22767	0.25	0.5	8	4	0.03	<0.03	2	0.25
<i>B. bombi</i> DSM 19703	<0.03	1	8	4	0.0625	0.5	0.5	1
<i>B. boum</i> LMG 10736	<0.03	0.25	512	256	0.0625	0.125	32	0.5
<i>B. breve</i> LMG 13208	0.0625	0.5	64	16	0.125	0.03	0.5	0.5
<i>B. callitrichos</i> DSM 23973	0.0625	0.5	256	64	0.25	0.03	8	0.5
<i>B. catenulatum</i> LMG 11043	<0.03	0.5	128	>512	0.0625	1	1	1
<i>B. choerinum</i> LMG 10510	0.25	0.25	128	64	0.125	2	0.5	1
<i>B. coryneforme</i> LMG 18911	0.25	0.5	32	16	0.0625	0.0625	4	2
<i>B. crudilactis</i> LMG 23609	0.125	1	16	32	0.25	1	4	2
<i>B. cuniculi</i> LMG 10738	0.5	0.5	32	32	0.125	1	2	1
<i>B. dentium</i> LMG 11045 (Bd1)	0.25	0.5	32	32	0.125	0.03	0.5	1
<i>B. eulemuris</i> LMM E3	0.5	1	32	64	0.125	0.5	0.5	1
<i>B. gallicum</i> LMG 11596	0.25	0.5	64	16	<0.03	0.0625	0.5	0.5
<i>B. gallinarum</i> LMG 11586	0.03	0.5	64	>512	<0.03	0.5	1	1
<i>B. hapali</i> MRM 8.14	0.25	0.5	64	16	0.0625	<0.03	0.5	1
<i>B. indicum</i> LMG 11587	0.25	1	32	128	64	512	16	2
<i>B. kashiwanohense</i> DSM 21854	0.5	0.5	128	64	32	256	0.5	1
<i>B. lemurum</i> LMC13	0.5	1	64	32	0.03	<0.03	0.5	1
<i>B. longum</i> subsp. <i>infantis</i> ATCC 15697	0.125	0.5	8	>512	0.125	0.0625	4	0.5
<i>B. longum</i> subsp. <i>longum</i> LMG 13197	0.5	0.5	32	64	0.125	<0.03	1	1
<i>B. longum</i> subsp. <i>suis</i> LMG 21814	<0.03	1	32	>512	0.0625	0.03	16	1
<i>B. magnum</i> LMG 11591	<0.03	0.25	8	8	<0.03	0.03	16	1
<i>B. merycicum</i> LMG 11341	0.0625	0.5	64	64	0.125	0.03	16	1
<i>B. minimum</i> LMG 11592	0.5	0.5	64	16	0.25	0.25	0.5	2
<i>B. mongoliense</i> DSM 21395	0.25	1	16	8	0.25	0.0625	0.5	1
<i>B. moukalabense</i> DSM 27321	0.125	0.5	128	128	0.125	1	0.5	0.5
<i>B. myosotis</i> MRM 5.9	0.5	0.25	32	32	0.03	<0.03	0.25	1
<i>B. pseudocatenulatum</i> LMG 10505	0.0625	0.25	128	64	0.25	0.03	16	1
<i>B. pseudolongum</i> subsp. <i>globosum</i> LMG 11569	0.125	0.5	128	128	0.0625	1	8	1
<i>B. pseudolongum</i> subsp. <i>pseudolongum</i> LMG 11571	0.0625	0.25	64	128	0.125	0.125	2	1
<i>B. psychraerophilum</i> LMG 21775	0.125	0.5	64	32	0.0625	1	4	2
<i>B. pullorum</i> LMG 21816	1	0.25	32	16	64	>1,024	32	2
<i>B. reuteri</i> DSM 23975	0.125	0.5	32	16	0.25	0.5	0.25	0.5
<i>B. ruminantium</i> LMG 21811	0.25	0.25	16	8	0.125	1	0.25	0.5
<i>B. saeculare</i> LMG 14934	0.125	0.5	64	>512	256	1	16	0.5
<i>B. saguini</i> DSM 23967	0.5	0.5	64	16	0.25	1	1	1
<i>B. scardovii</i> LMG 21589	0.5	0.5	64	16	0.25	0.25	1	1
<i>B. stellenboschense</i> DSM 23968	<0.03	0.5	16	16	0.0625	0.03	0.5	0.5
<i>B. stercoris</i> DSM 24849	0.0625	0.5	64	64	0.25	0.03	16	1
<i>B. subtile</i> LMG 11597	0.25	0.5	64	32	0.0625	0.5	1	1
<i>B. thermacidophilum</i> subsp. <i>porcinum</i> LMG 21689	0.03	0.25	256	128	0.125	0.0625	1	0.5
<i>B. thermacidophilum</i> subsp. <i>thermacidophilum</i> LMG 21395	0.125	0.25	16	64	0.125	0.125	0.5	2
<i>B. thermophilum</i> JCM 1207	0.0625	0.25	256	128	0.125	0.0625	1	0.5
<i>B. tissieri</i> MRM 5.18	2	0.25	128	64	0.03	0.03	1	1
<i>B. tsurumiense</i> JCM 13495	0.125	0.5	128	64	0.5	2	1	1

dobacterial species belonging to the QPS list. In contrast, we observed susceptibility variations to streptomycin and tetracycline at the intraspecific level for *B. bifidum* as well as *B. breve* and for *B. bifidum*, *B. animalis*, and *B. adolescentis*, respectively (Table 2). This information indicates that antibiotic resistance in bifidobacteria does not appear to follow a vertical route of evolution but may have been acquired through horizontal gene transfer, in a fashion similar to that previously observed for other gut commensal microorganisms (7).

TABLE 2 Antibiotic sensitivity of different strains belonging to the QPS list

Species	Strain	Resistance data ($\mu\text{g/ml}$) for:								
		Ampicillin	Vancomycin	Gentamicin	Streptomycin	Erythromycin	Clindamycin	Tetracycline	Chloramphenicol	
<i>B. bifidum</i>	PRL2010	0.0625	1	64	32	0.125	<0.03	1	1	
	LMG13195	<0.03	0.5	64	>1,024	0.0625	0.03	0.5	0.5	
	LMG11041	<0.06	0.25	8	8	0.125	<0.06	0.5	0.5	
	IPLA20017	0.03	0.5	32	>1,024	0.125	0.0625	0.5	0.5	
	IPLA20015	0.0625	0.5	32	>1,024	0.0625	0.0625	8	0.5	
	A8	0.03	1	64	8	0.0625	0.03	0.5	0.5	
	156B	0.0625	0.5	64	16	0.03	0.0625	1	1	
	85B	0.0625	0.5	32	16	0.03	0.0625	1	0.5	
	324B	0.0625	1	64	16	0.0625	0.0625	1	0.5	
	LMG13200	0.5	0.5	16	256	0.0625	0.25	8	0.5	
	LMG11583	0.5	0.5	32	16	0.03	0.25	16	1	
	LMG11582	0.5	0.5	32	>1,024	0.125	0.25	16	0.5	
	<i>B. breve</i>	689B	0.5	0.5	32	>1,024	0.125	0.25	0.5	0.5
		DSM20213	0.0625	0.5	64	16	0.125	0.03	0.5	0.5
12L		0.25	1	32	32	0.125	0.25	0.5	0.5	
2L		0.25	1	16	32	0.125	0.25	0.25	0.5	
D1-16		0.25	0.5	8	>1,024	0.125	<0.03	0.5	1	
31L		0.5	1	32	>1,024	0.125	<0.03	0.5	0.5	
UCC2003		0.125	1	64	32	0.25	0.5	0.125	1	
<i>B. animalis</i> subsp. <i>lactis</i>		BI12	0.125	0.5	128	64	0.25	4	8	2
	BLC1	0.125	0.5	128	64	0.25	4	8	2	
	DSM10140	0.125	0.5	128	64	0.25	4	8	2	
	646	0.125	0.5	128	64	0.25	4	8	2	
	BB12	0.125	0.5	128	64	0.25	4	8	2	
	ADO11	0.125	0.5	128	64	0.25	4	8	2	
<i>B. animalis</i> subsp. <i>animalis</i>	ATCC25527	0.125	0.5	64	32	0.25	4	1	2	
<i>B. adolescentis</i>	22L	<0.03	0.25	32	32	0.5	<0.03	0.5	2	
	ATCC15703	0.0625	0.5	128	32	0.0625	0.03	1	1	
	LMG18897	<0.03	0.25	16	32	0.25	<0.03	0.25	2	
	LMG11579	0.25	0.25	32	32	1	1	16	1	
	LMG10733	0.0625	0.25	64	32	0.25	<0.03	1	0.5	
	LMG10734	0.125	0.25	64	32	0.5	<0.03	0.5	2	
	42B	0.0625	0.25	32	16	0.25	<0.03	0.5	2	
	70B	0.0625	0.25	64	64	0.25	0.03	0.5	2	
	487B	<0.03	0.25	32	32	0.5	0.125	0.5	2	
	703B	0.25	0.25	64	32	0.5	<0.03	1	2	
	AD2-8	0.03	0.25	16	32	0.25	<0.03	0.5	2	
	AL12-4	0.0625	0.25	32	16	0.5	<0.03	1	2	
	AL46-2	1	<0.03	32	32	<0.03	0.125	16	0.5	
	AL46-7	0.0625	0.25	32	16	0.25	0.25	16	2	
	JCM15918	0.0625	0.5	64	64	0.25	0.03	16	1	
<i>B. longum</i> subsp. <i>longum</i>	296B	0.125	0.5	32	64	<0.03	<0.03	1	2	
	LMG13197	0.5	0.5	32	64	0.125	<0.03	1	1	
	B2A2	0.125	0.25	32	64	0.0625	<0.03	1	1	

Prediction of the bifidobacterial resistome. The genomes of 91 bifidobacterial strains that had been assessed for their susceptibility to antibiotics (see above) were screened for putative AR genes. This analysis was performed using the CARD AR gene database (16), to which two genes, predicted to encode aminoglycoside phosphotransferases (APH), had been added. Notably, the presence of these two genes in *B. breve* has previously been shown to be associated with resistance to gentamicin, streptomycin, and kanamycin (17). These *in silico* analyses revealed that the resistome of the genus *Bifidobacterium* is predicted to consist of 783 genes (see Table S1 in the supplemental material). Of the AR genes identified, 47% were shown to be conserved in the 54 (sub)species of the genus *Bifidobacterium*, thus representing bifidobacterial core genome sequences (12, 18). While 74% of these genes encode β -lactamases, 26% are involved in antimicrobial peptide resistance (Table S1). Interestingly, analysis of chromosomal sequences revealed the presence of a single copy of a predicted APH-

encoding gene in all *Bifidobacterium* strains. Furthermore, in 20 bifidobacterial genomes, we identified two copies of such a putative APH-encoding gene, which may account for higher resistance toward streptomycin and gentamicin in these bifidobacterial strains (see Table S2 in the supplemental material). In contrast, *tet(W)* homologs, previously identified in *Bifidobacterium animalis* subsp. *lactis* (19, 20), are present in the genomes of 11 bifidobacterial species (Fig. 2), based on *in silico tet(W)* domain prediction, thus highlighting the fact that this AR gene represents a relatively broad species-specific genetic signature within the bifidobacterial pan-genome. Notably, *in vitro*-based MIC assays involving these strains revealed high resistance toward tetracycline (from 8 $\mu\text{g/ml}$ to 32 $\mu\text{g/ml}$), consistent with the presence of the *tet(W)* gene in their genomes (Fig. 2). In addition, tetracycline resistance may be conferred by additional genetic features, since *Bifidobacterium indicum* LMG 11587 and *Bifidobacterium callitrichos* DSM 23973 encompass no less than three *tet(W)* domains (Fig. 2).

When the antibiotic susceptibility data were coupled to the predicted resistome information, we were able to detect good correspondence between phenotype and genotype. For instance, in *B. indicum* LMG 11587 and *Bifidobacterium coryneforme* LMG 18911, different susceptibilities to streptomycin, erythromycin, clindamycin and tetracycline were identified, which appeared to be supported by the genotypic data. Recently, Lugli et al. (12) highlighted that a very close genetic relatedness exists between *B. indicum* LMG11587 and *B. coryneforme* LMG18911 (average nucleotide identity [ANI] value of 98.13). Comparative genomic analysis involving the chromosomal sequences of these strains allowed the identification of genes that are absent in the genome of *B. coryneforme* LMG 18911 (Fig. 3). Interestingly, an in-depth functional analysis of the *B. indicum* LMG 11587 unique genes highlighted the presence of an open reading frame (ORF) predicted to encode a major facilitator superfamily (MFS) transporter that is classified as a member of the drug:H⁺-antiporter-3 (12 spanner) (DHA3) family, which may be responsible for the extrusion of erythromycin, streptomycin, and clindamycin from the (bifido)bacterial cell (Fig. 3). Similarly, *Bifidobacterium pullorum* LMG 21816 was shown to exhibit a high level of resistance against clindamycin (>1,024 $\mu\text{g/ml}$) compared to that identified for other type strains of the 54 (sub)species of the genus *Bifidobacterium*. Comparative genomics involving all type strains of the genus showed 138 protein-encoding genes that appeared to be unique to *B. pullorum* LMG21816. Notably, one of these genes (BPULL_1285) was predicted to encode an MFS transporter classified as a DHA3 family transporter. This putative multidrug transporter may thus be responsible for the noted resistance to clindamycin as also observed for *B. coryneforme* LMG 18911. Nonetheless, in five cases, *Bifidobacterium catenulatum* LMG 11043, *Bifidobacterium gallinarum* LMG 11586, *Bifidobacterium longum* subsp. *infantis* ATCC 15697, *Bifidobacterium longum* subsp. *suis* LMG 21814, and *Bifidobacterium saeculare* LMG 14934 (Table S1), the observed high resistance to streptomycin (>512 $\mu\text{g/ml}$) does not appear to be associated with the presence of a specific AR gene. This resistance may therefore either be due to a point mutation in a particular chromosomal gene causing innate resistance against streptomycin or be caused by high expression of a particular AR gene. Furthermore, based on the reconstruction of the genetic evolution of species of the genus *Bifidobacterium* based on their pan-genomes (11), we predicted the genetic origins of AR identified in bifidobacteria. Notably, 6% of the predicted bifidobacterial resistome appears to be acquired from other microbial genera such as *Gardnerella* and *Lactobacillus*, representing bacterial taxa that share the same environmental niche as bifidobacteria (Table S1). Nonetheless, we cannot exclude the possibility that these genes might be received independently from another common source. These findings therefore suggest that a sizeable portion of the genetic AR arsenal of bifidobacteria has been acquired by means of HGT events.

Identification of putative mobile bifidobacterial AR genes. In order to evaluate the occurrence of bifidobacterial AR genes located on or in the proximity of mobile elements such as episomes, conjugative transposons, and prophages, we analyzed the



FIG 2 Comparison of *tet(W)* gene identified in *B. animalis* subsp. *lactis* with the corresponding domains from all type strains of bifidobacteria. The top part of the figure depicts a schematic representation of the different domains identified in *tet(W)*. The heat map displays an *in silico* prediction of domains encoded by *tet(W)* and the breakpoint value for tetracycline in all type strains belonging to the *Bifidobacterium* genus. The red color indicates gene presence, and the black color represents their absence.




FIG 3 Unique genetic loci identified in the genome of *B. indicum* LMG 11587 and *B. pullorum* LMG 21816. On the left, a circular genome atlas of *B. indicum* LMG 11587 (orange circle) and *B. coryneforme* LMG 18911 (green circle) are shown, while on the right, the same representation is proposed for the *B. pullorum* LMG 21816 genome (blue circles). Internal circles represent the G+C percent deviation followed by the GC skew (G–C/G+C). In the reported genetic maps, each arrow indicates an ORF where the red ones correspond to the major facilitator superfamily (MFS) identified in *B. indicum* LMG 11587 (orange arrows) and *B. pullorum* LMG 21816 (blue arrows).

flanking DNA sequences of the predicted AR genes (see Tables S1 and S3 in the supplemental material). Such genetic elements may be responsible for AR gene mobilization from and/or to other microorganisms. Homology-based analyses of the surrounding DNA regions of the predicted bifidobacterial AR genes were performed and combined with outputs of the software package COLOMBO (21). These analyses identified 208 AR genes placed within genomic regions that have putatively been acquired by HGT, thus representing the predicted horizontally acquired bifidobacterial resistome (HABR) (Fig. 4). Notably, HABR represents about 27% of the predicted bifidobacterial resistome, disregarding the proximity of the genes to transposable elements. Taken together, these results suggest that a substantial proportion of the bifidobacterial AR genes identified were acquired by HGT. Furthermore, *in silico* analysis disclosed that only seven of the AR genes identified are placed near a predicted prophage, while two are adjacent to putative plasmid replication genes.

Remarkably, we noticed that the largest part of the predicted bifidobacterial HABR is directed toward glycopeptides (12%), followed by β -lactamase-encoding genes (10%) (Fig. 4a). Furthermore, the AR genes flanking prophage and plasmid DNA regions are represented by genes predicted to encode bleomycin, kanamycin, and bacitracin resistance (Table S1). Another intriguing bifidobacterial mobile AR gene predicted to be carried on a conjugative transposon is represented by the *tet(W)* gene, which is found flanking a mobile element in the genomes of all of the *B. animalis* subsp. *lactis* strains analyzed (Fig. 4b). Such findings confirm previous genomic data about this bifidobac-




FIG 4 Distribution of mobile bifidobacterial AR genes. (a) The left pie chart represents chromosomal bifidobacterial AR genes that are (red) or are not (blue) predicted to be acquired by HGT, and the pie chart on the right displays the classification of such predicted HGT-acquired AR genes. (b to e) Bifidobacterial genomic regions containing putative AR genes (green arrows) located near mobile elements (red arrows) belonging to *B. animalis* subsp. *lactis*, *B. adolescentis*, and *B. bifidum*, respectively.

terial taxon (19) and support the hypothesis that this resistance is due to a mobile *tet(W)* gene representing a common genetic feature of *B. animalis* subsp. *lactis*. Furthermore, we identified a putative mobile AR gene that encodes a predicted aminoglycoside protein with an APH domain for kanamycin resistance in all publicly available genomes of *B. animalis* subsp. *lactis* (Fig. 4c; see also Table S3 in the supplemental material). Yet another intriguing example is represented by analysis of the genomes of *B. adolescentis*, of which eight encompass an AR gene predicted to exert resistance against bleomycin, located within 4 kb from a putative mobile element (Fig. 4d and Table S3). Remarkably, seven strains of *B. bifidum* exhibit β -lactamase-encoding genes near truncated transposases (Fig. 4e and Table S3). Nevertheless, none of these transposase-encoding genes can be classified as a conjugal transposon, thus reducing the possibility of AR gene mobilization by HGT. These findings indicate that only a small fraction (1%) of the predicted resistome found in the genus *Bifidobacterium* resides in nearby mobile elements, which may facilitate AR gene transfer to other bacteria. The distribution of AR genes in bifidobacteria may thus be due to selective pressure imposed by extensive antibiotic use in their animal and human hosts in a fashion that is similar to what has previously been observed for other lactic acid bacteria (LAB) such as *Lactobacillus* (22), a phenomenon that is considered to represent microbe-host coevolution.

Metagenome analysis targeting bifidobacterial AR. Bifidobacteria have predominantly been isolated from the mammalian GIT (23), where their functional contribution




FIG 5 Metagenomic abundance of bifidobacterial AR genes. (a) Average abundance of bifidobacterial reads retrieved in the metagenome samples of infants (healthy and preterm), children treated with antibiotics, and adults. (b) Abundance of different classes of bifidobacterial AR genes with respect to the total BGS identified in the samples. (c) Average abundance of bifidobacterial AR reads with respect to the total BGS retrieved in the metagenomes, where each number corresponds to the days following birth of healthy infants (H) or preterm infants (P).

in terms of metabolism of various dietary carbohydrates and host glycans has been investigated (11, 18, 24–26). However, their contribution to the resistome of the mammalian gut microbiome has not been studied in any great detail. We therefore assessed the presence of AR-encoding bifidobacterial DNA sequences within two gut metagenome data sets from healthy human beings, including adult gut microbiomes (27) and infant gut microbiomes (<https://www.broadinstitute.org/scientific-community/science/projects/microbiome-projects>), which in both cases had been collected from U.S. citizens (see Table S4 in the supplemental material). In addition, we explored the bifidobacterial AR contribution to the resistomes of preterm infant gut microbiomes (<https://www.broadinstitute.org/scientific-community/science/projects/microbiome-projects>) and of 2- to 7-year-old children who had received intensive antibiotic treatment, i.e., a combination of β -lactams and macrolides (28). These metagenomic data sets were assayed for the presence of bifidobacteria by searching for bifidobacterial gene sequences (BGS), i.e., the presence of any of the combined genes collected from the 91 taxa analyzed. The minimum coverage of each gene included in the BGS collection was computed based on the metagenomic reads with 98% full-length identity. As displayed in Fig. 5, healthy infants showed a higher average percentage of metagenomic reads that correspond to BGS (6.1%, $P < 0.001$), ranging from 0.01% to 52%, than adults (0.1%), while preterm infants and children treated with antibiotics exhibited an average of 1.5%. This is consistent with previous findings supporting the ecological behavior of bifidobacteria as core gut microorganisms of the healthy human gut during the suckling stage (2, 23, 29–36). Furthermore, our analysis revealed reduced bifidobacterial populations in preterm infants and children extensively treated with antibiotics, which is consistent with the existing literature (37).

The bifidobacterial AR genes collected from the genomic analysis allowed us to evaluate the contribution of the bifidobacterial resistome with respect to the total BGS identified in each sample. Interestingly, among the most frequently represented bifidobacterial AR genes in the metagenomic data sets from adult samples, an extensive repertoire of specific AR-encoding genes, such as those specifying β -lactamases, which confer resistance against penicillin, cephalosporin, carbapenem, and monobactam, is noteworthy, followed by genes that specify glycopeptide and aminoglycoside resistance (Fig. 5b). Such findings reinforce the notion that despite the lower abundance of bifidobacteria detected in the adult human gut, their functional contribution to the human gut microbiome may be important in terms of expanding the overall resistome of the human gut and thus affecting the maintenance of a gut climax following antibiotic therapies. Of note, the bifidobacterial AR-encoding gene distribution within the infant's microbiome was shown to be similar to that of adults with a preponderance of β -lactamase-encoding genes (Fig. 5b).

The availability of microbiomes from the Metagenome from Infant Gut project collected at different time points, i.e., 7, 14, 21, 60, 150, and 360 days, allowed us to evaluate the dynamics of bifidobacterial AR-encoding genes during the first year of life of healthy and preterm infants. Looking at the overall representation of bifidobacterial AR reads in the metagenomic data sets, a lower value is obtained for healthy and preterm infants in the first week of life, followed by an increase, which then stabilizes during a 60- to 360-day period, thus being comparable with an adult's profile (Fig. 5c). In contrast, in the metagenome data set of children extensively treated with antibiotics, we observed a higher abundance of bifidobacterial AR reads (1.34%, $P < 0.006$), suggesting the increased presence of bifidobacterial species that tolerate the administered dosage of antibiotics assumed during treatment (Fig. 5c). Furthermore, we observed a higher abundance in β -lactamase reads (0.99% of the bifidobacterial reads, $P < 0.001$) in the antibiotic-treated children with respect to those in the other three groups (ranging from 0.29% to 0.43%) (Fig. 5b), reflecting the antibiotic treatment provided. Accordingly, during the first days following birth, the infants' microbiota may be more sensitive to antibiotic treatment due to a very simple and fragile bifidobacterial community, which appears to be unable to cope with a high level of antibiotic administration. Thus, the particular antibiotic administered to the newborn may bring about an intestinal microbiota disturbance that can prevent or delay subsequent development of a normal microbiota (38).

In conclusion, bifidobacteria are dominant members of the infant gut microbiota, and their contribution to host health is well documented (24). Despite many reports investigating the susceptibility of human bifidobacterial species to various antibiotics, very little is known about their resistome. In this study, we performed a detailed assessment of the genetic traits that support antibiotic resistance in bifidobacteria. Notably, varying susceptibilities to antibiotics at the intraspecific level were identified for certain bifidobacterial species, an observation of relevance with respect to the scientific rationale for breakpoint values proposed by EFSA (15), as currently employed breakpoint values are based on MIC values determined for a single bifidobacterial strain. In addition, based on our analyses, the identification of higher MIC values with respect to breakpoint values proposed by EFSA does not always correspond with the occurrence of predicted mobile AR genes and thus does not necessarily pose any risk of genetic transferability. Interestingly, the resistome of bifidobacteria represents a substantial proportion of the predicted mobilome of the genus *Bifidobacterium*, thus supporting the hypothesis that the antibiotic era has somehow shaped the pangenome of this group of commensal microorganisms. Notably, a similar trend has already been observed for other gut commensal microorganisms such as *Lactobacillus* (22). Acquisition of resistance to antibiotics represents a way used by bacteria to survive and thus to increase their ecological fitness (39). Characterization of the bifidobacterial resistome allowed us to obtain insights into the manner by which the bifidobacterial community contributes to the overall gut microbiota resistome. Our data show that the bifidobacterial communities in the infant gut possess a reduced AR arsenal compared

to that present in the bifidobacterial gut microbiota of an older child. These data reinforce the notion that the infant gut microbiota, particular that present during the first weeks following birth, is more prone to perturbations following antibiotic therapy and may thus be highly susceptible to long-term disturbances, compared to the stable and more robust (adult) gut microbiota that develops subsequently.

MATERIALS AND METHODS

Bacterial strains. All type strains belonging to the *Bifidobacterium* genus and several previously characterized strains belonging to species present on the qualified presumption of safety (QPS) list (11, 13, 19, 40–44) were used in this study (Tables 1 and 2). Cultures were grown under anaerobic conditions (2.99% H₂, 17.01% CO₂, and 80% N₂) in a chamber (Concept 400; Ruskin) on De Man-Rogosa-Sharpe (MRS) broth (Scharlau Chemie, Barcelona, Spain) supplemented with 0.05% (wt/vol) L-cysteine hydrochloride and were incubated at 37°C. Prior to performance of the antibiotic susceptibility test, strains were precultivated (to allow adaptation) in the same medium used for the susceptibility test, based on the use of Iso-Sensitest (IST) broth (Oxoid).

Antibiotic susceptibility tests. For selected *Bifidobacterium* strains, the MIC breakpoints (micrograms per milliliter) of eight antibiotics (ampicillin, vancomycin, gentamicin, streptomycin, erythromycin, clindamycin, tetracycline, and chloramphenicol) were determined using the broth microdilution method (MDL) according to the ISO standard guidelines (15). All antibiotics were purchased from Sigma-Aldrich (Italy). Microplates were incubated under anaerobic conditions for 48 h at 37°C. Cell density was monitored by optical density measurements at 600 nm (OD₆₀₀) using a plate reader (BioTek, VT, USA). The MIC breakpoint represents the highest concentration of a given antibiotic to which a particular bacterial strain is resistant.

Antibiotic resistance gene prediction. The *in silico* proteome of 93 *Bifidobacterium* strains (Tables 1 and 2) was screened for enzymes that act as antibiotic inactivators using a custom script based on RapSearch2 software (45) and the database CARD (16). We decided not to include transporters in our analyses due to the low accuracy with which antibiotic transporters can be predicted.

Prediction of the mobile bifidobacterial AR genes. The bifidobacterial strains used in this study were screened for genomic islands, evaluating the genes flanking the predicted AR genes in the range of 10 kb, using homology searches (46) and the software COLOMBO (21). Putative mobile elements such as episomes, conjugative transposons, and prophages were predicted through homology searches against in-house-generated databases (<http://probiogenomics.unipr.it/sw/MobElemDB.zip>), including genes retrieved from the National Center for Biotechnology Information (NCBI) database.

***In silico* analysis for resistome reconstruction.** All identified bifidobacterial AR genes were aligned with whole-genome sequencing (WGS) reads previously deposited at the NCBI (Sequence Read Archive [SRA] BioProject). This information was obtained from shotgun sequencing microbiome data sets of (fecal samples of) healthy adults from the Human Microbiome Project (PRJNA48479), healthy and preterm infants from the Metagenome from Infant Gut project (PRJNA63661), and children with high-frequency antibiotic treatment from the Child Gut Microbiome under Antibiotics project (PRJEB11685). Metagenomic data sets were filtered using the fastq-mcf script (<https://expressionanalysis.github.io/ea-utils/>) (minimum mean quality score, 20; window size, 5; quality threshold, 25; and minimum length, 80) to achieve high-quality reads exclusively. The resulting reads were aligned against the human genome using the Burrows-Wheeler Aligner program (47) (BWAMEM algorithm with trigger reseeding, 1.5; minimum seed length, 19; matching score, 1; mismatch penalty, 4; gap open penalty, 6; and gap extension penalty, 1) and further processed with the SAMtools software package (48) in order to remove human reads. The final mapping against putative bifidobacterial AR genes was performed using Bowtie 2 (49) through multiple-hit mapping and “very-sensitive” policy. The mapping was performed using a minimum score threshold function ($-\text{score-min } C, -13, 0$) in order to limit reads of arbitrary length to two mismatches and retain those matches with at least 98% full-length identity. The software employed to calculate read counts corresponding to either bifidobacterial genes or bifidobacterium-specific AR genes was HTSeq (50) (running in union mode). The percentages of bifidobacterial genes for each sample were based on the total amount of filtered reads, while the percentages of bifidobacterial AR genes reported were based on the counts of reads mapped to bifidobacterial genes in each sample.

Statistical analysis. SPSS software (IBM, Italy) was used to perform statistical analysis between groups by an analysis of variance (ANOVA) test.

Accession number(s). The bifidobacterial sequences reported in this article have been deposited in the GenBank database under accession numbers MLZK00000000 and MLZL00000000. The versions described in this paper are MLZK01000000 and MLZL01000000.

SUPPLEMENTAL MATERIAL

Supplemental material for this article may be found at <https://doi.org/10.1128/AEM.02894-16>.

DATASET S1, XLSX file, 0.1 MB.

ACKNOWLEDGMENTS

This work was funded by the EU Joint Programming Initiative, A Healthy Diet for a Healthy Life (JPI HDHL, <http://www.healthydietforhealthylife.eu/>) through MIUR and

Science Foundation Ireland (SFI) to M.V. and D.V.S., respectively. We thank GenProbio srl for financial support of the Laboratory of Probiogenomics. S.D. is supported by Fondazione Caritro, Trento, Italy. L.M. is supported by Fondazione Cariparma, Parma, Italy. D.V.S. is a member of The APC Microbiome Institute funded by SFI (grant SFI/12/RC/2273).

We thank Paola Mattarelli for sharing bifidobacterial isolates.

We declare that we have no competing interests.

REFERENCES

- Young VB. 2012. The intestinal microbiota in health and disease. *Curr Opin Gastroenterol* 28:63–69. <https://doi.org/10.1097/MOG.0b013e32834d61e9>.
- Turroni F, Peano C, Pass DA, Foroni E, Severgnini M, Claesson MJ, Kerr C, Hourihane J, Murray D, Fuligni F, Gueimonde M, Margolles A, De Bellis G, O'Toole PW, van Sinderen D, Marchesi JR, Ventura M. 2012. Diversity of bifidobacteria within the infant gut microbiota. *PLoS One* 7:e36957. <https://doi.org/10.1371/journal.pone.0036957>.
- Marshall BM, Levy SB. 2011. Food animals and antimicrobials: impacts on human health. *Clin Microbiol Rev* 24:718–733. <https://doi.org/10.1128/CMR.00002-11>.
- Francino MP. 2015. Antibiotics and the human gut microbiome: dysbioses and accumulation of resistances. *Front Microbiol* 6:1543. <https://doi.org/10.3389/fmicb.2015.01543>.
- Ouwehand AC, Forssten S, Hibberd AA, Lyra A, Stahl B. 2016. Probiotic approach to prevent antibiotic resistance. *Ann Med* 48:246–255. <https://doi.org/10.3109/07853890.2016.1161232>.
- Goossens H, Ferech M, Stichele RV, Elseviers M, Grp EP. 2005. Outpatient antibiotic use in Europe and association with resistance: a cross-national database study. *Lancet* 365:579–587. [https://doi.org/10.1016/S0140-6736\(05\)70799-6](https://doi.org/10.1016/S0140-6736(05)70799-6).
- Huddleston JR. 2014. Horizontal gene transfer in the human gastrointestinal tract: potential spread of antibiotic resistance genes. *Infect Drug Resist* 7:167–176. <https://doi.org/10.2147/IDR.S48820>.
- Arbolea S, Sanchez B, Milani C, Duranti S, Solis G, Fernandez N, de los Reyes-Gavilan CG, Ventura M, Margolles A, Gueimonde M. 2015. Intestinal microbiota development in preterm neonates and effect of perinatal antibiotics. *J Pediatr* 166:538–544. <https://doi.org/10.1016/j.jpeds.2014.09.041>.
- Fouhy F, Guinane CM, Hussey S, Wall R, Ryan CA, Dempsey EM, Murphy B, Ross RP, Fitzgerald GF, Stanton C, Cotter PD. 2012. High-throughput sequencing reveals the incomplete, short-term recovery of infant gut microbiota following parenteral antibiotic treatment with ampicillin and gentamicin. *Antimicrob Agents Chemother* 56:5811–5820. <https://doi.org/10.1128/AAC.00789-12>.
- Patel AR, Shah NP, Prajapati JB. 2012. Antibiotic resistance profile of lactic acid bacteria and their implications in food chain. *World J Dairy Food Sci* 7:202–211.
- Milani C, Lugli GA, Duranti S, Turroni F, Bottacini F, Mangifesta M, Sanchez B, Viappiani A, Mancabelli L, Taminiau B, Delcenserie V, Barrancou R, Margolles A, van Sinderen D, Ventura M. 2014. Genomic encyclopedia of type strains of the genus *Bifidobacterium*. *Appl Environ Microbiol* 80:6290–6302. <https://doi.org/10.1128/AEM.02308-14>.
- Lugli GA, Milani C, Turroni F, Duranti S, Ferrario C, Viappiani A, Mancabelli L, Mangifesta M, Taminiau B, Delcenserie V, van Sinderen D, Ventura M. 2014. Investigation of the evolutionary development of the genus *Bifidobacterium* by comparative genomics. *Appl Environ Microbiol* 80:6383–6394. <https://doi.org/10.1128/AEM.02004-14>.
- European Food Safety Authority. 2015. Scientific opinion on the maintenance of the list of QPS biological agents intentionally added to food and feed (2013 update). *EFSA J* 11:3449.
- Merenstein DJ, Tan TP, Molokin A, Smith KH, Roberts RF, Shara NM, Mete M, Sanders ME, Solano-Aguilar G. 2015. Safety of *Bifidobacterium animalis* subsp. *lactis* (B. *lactis*) strain BB-12-supplemented yogurt in healthy adults on antibiotics: a phase I safety study. *Gut Microbes* 6:66–77. <https://doi.org/10.1080/19490976.2015.1005484>.
- European Food Safety Authority. 2012. Guidance on the assessment of bacterial susceptibility to antimicrobials of human and veterinary importance. *EFSA J* 10:2740.
- McArthur AG, Waglechner N, Nizam F, Yan A, Azad MA, Baylay AJ, Bhullar K, Canova MJ, De Pascale G, Ejim L, Kalan L, King AM, Koteva K, Morar M, Mulvey MR, O'Brien JS, Pawlowski AC, Piddock LJ, Spanogiannopoulos P, Sutherland AD, Tang I, Taylor PL, Thaker M, Wang W, Yan M, Yu T, Wright GD. 2013. The comprehensive antibiotic resistance database. *Antimicrob Agents Chemother* 57:3348–3357. <https://doi.org/10.1128/AAC.00419-13>.
- Fouhy F, O'Connell Motherway M, Fitzgerald GF, Ross RP, Stanton C, van Sinderen D, Cotter PD. 2013. In silico assigned resistance genes confer *Bifidobacterium* with partial resistance to aminoglycosides but not to beta-lactams. *PLoS One* 8:e82653. <https://doi.org/10.1371/journal.pone.0082653>.
- Milani C, Lugli GA, Duranti S, Turroni F, Mancabelli L, Ferrario C, Mangifesta M, Hevia A, Viappiani A, Scholz M, Arioli S, Sanchez B, Lane J, Ward DV, Hickey R, Mora D, Segata N, Margolles A, van Sinderen D, Ventura M. 2015. Bifidobacteria exhibit social behavior through carbohydrate resource sharing in the gut. *Sci Rep* 5:15782. <https://doi.org/10.1038/srep15782>.
- Milani C, Duranti S, Lugli GA, Bottacini F, Strati F, Arioli S, Foroni E, Turroni F, van Sinderen D, Ventura M. 2013. Comparative genomics of *Bifidobacterium animalis* subsp. *lactis* reveals a strict monophyletic bifidobacterial taxon. *Appl Environ Microbiol* 79:4304–4315. <https://doi.org/10.1128/AEM.00984-13>.
- Gueimonde M, Florez AB, van Hoek AH, Stuer-Lauridsen B, Stroman P, de los Reyes-Gavilan CG, Margolles A. 2010. Genetic basis of tetracycline resistance in *Bifidobacterium animalis* subsp. *lactis*. *Appl Environ Microbiol* 76:3364–3369. <https://doi.org/10.1128/AEM.03096-09>.
- Waack S, Keller O, Asper R, Brodag T, Damm C, Fricke WF, Surovcik K, Meinicke P, Merkl R. 2006. Score-based prediction of genomic islands in prokaryotic genomes using hidden Markov models. *BMC Bioinformatics* 7:142. <https://doi.org/10.1186/1471-2105-7-142>.
- Gueimonde M, Sanchez B, de Los Reyes-Gavilan CG, Margolles A. 2013. Antibiotic resistance in probiotic bacteria. *Front Microbiol* 4:202. <https://doi.org/10.3389/fmicb.2013.00202>.
- Ventura M, Turroni F, Motherway MO, MacSharry J, van Sinderen D. 2012. Host-microbe interactions that facilitate gut colonization by commensal bifidobacteria. *Trends Microbiol* 20:467–476. <https://doi.org/10.1016/j.tim.2012.07.002>.
- Turroni F, Ventura M, Butto LF, Duranti S, O'Toole PW, Motherway MO, van Sinderen D. 2014. Molecular dialogue between the human gut microbiota and the host: a *Lactobacillus* and *Bifidobacterium* perspective. *Cell Mol Life Sci* 71:183–203. <https://doi.org/10.1007/s00018-013-1318-0>.
- Bottacini F, Ventura M, van Sinderen D, O'Connell Motherway M. 2014. Diversity, ecology and intestinal function of bifidobacteria. *Microb Cell Fact* 13(Suppl 1):S4. <https://doi.org/10.1186/1475-2859-13-S1-S4>.
- Flint HJ, Scott KP, Duncan SH, Louis P, Forano E. 2012. Microbial degradation of complex carbohydrates in the gut. *Gut Microbes* 3:289–306. <https://doi.org/10.4161/gmic.19897>.
- Human Microbiome Project Consortium. 2012. Structure, function and diversity of the healthy human microbiome. *Nature* 486:207–214. <https://doi.org/10.1038/nature11234>.
- Korpela K, Salonen A, Virta LJ, Kekkonen RA, Forslund K, Bork P, de Vos WM. 2016. Intestinal microbiome is related to lifetime antibiotic use in Finnish pre-school children. *Nat Commun* 7:10410. <https://doi.org/10.1038/ncomms10410>.
- Avershina E, Lundgard K, Sekelja M, Dotterud C, Storro O, Oien T, Johnsen R, Rudi K. 2016. Transition from infant- to adult-like gut microbiota. *Environ Microbiol* 18:2226–2236. <https://doi.org/10.1111/1462-2920.13248>.
- Martin R, Makino H, Cetinyurek Yavuz A, Ben-Amor K, Roelofs M, Ishikawa E, Kubota H, Swinkels S, Sakai T, Oishi K, Kushihiro A, Knol J. 2016. Early-life events, including mode of delivery and type of feeding, siblings and gender, shape the developing gut microbiota. *PLoS One* 11:e0158498. <https://doi.org/10.1371/journal.pone.0158498>.
- Milani C, Hevia A, Foroni E, Duranti S, Turroni F, Lugli GA, Sanchez B,

- Martin R, Gueimonde M, van Sinderen D, Margolles A, Ventura M. 2013. Assessing the fecal microbiota: an optimized ion torrent 16S rRNA gene-based analysis protocol. *PLoS One* 8:e68739. <https://doi.org/10.1371/journal.pone.0068739>.
32. Milani C, Mancabelli L, Lugli GA, Duranti S, Turrone F, Ferrario C, Mangifesta M, Viappiani A, Ferretti P, Gorfer V, Tett A, Segata N, van Sinderen D, Ventura M. 2015. Exploring vertical transmission of bifidobacteria from mother to child. *Appl Environ Microbiol* 81:7078–7087. <https://doi.org/10.1128/AEM.02037-15>.
 33. Nuriel-Ohayon M, Neuman H, Koren O. 2016. Microbial changes during pregnancy, birth, and infancy. *Front Microbiol* 7:1031.
 34. Roger LC, Costabile A, Holland DT, Hoyles L, McCartney AL. 2010. Examination of faecal *Bifidobacterium* populations in breast- and formula-fed infants during the first 18 months of life. *Microbiology* 156:3329–3341. <https://doi.org/10.1099/mic.0.043224-0>.
 35. Turrone F, Duranti S, Bottacini F, Guglielmetti S, Van Sinderen D, Ventura M. 2014. *Bifidobacterium bifidum* as an example of a specialized human gut commensal. *Front Microbiol* 5:437.
 36. Yassour M, Vatanen T, Siljander H, Hamalainen AM, Harkonen T, Ryhanen SJ, Franzosa EA, Vlamakis H, Huttenhower C, Gevers D, Lander ES, Knip M, DIABIMMUNE Study Group, Xavier RJ. 2016. Natural history of the infant gut microbiome and impact of antibiotic treatment on bacterial strain diversity and stability. *Sci Transl Med* 8:343ra381. <https://doi.org/10.1126/scitranslmed.aad0917>.
 37. Hussey S, Wall R, Gruffman E, O'Sullivan L, Ryan CA, Murphy B, Fitzgerald G, Stanton C, Ross RP. 2011. Parenteral antibiotics reduce bifidobacteria colonization and diversity in neonates. *Int J Microbiol* 2011:130574. <https://doi.org/10.1155/2011/130574>.
 38. Gibson MK, Crofts TS, Dantas G. 2015. Antibiotics and the developing infant gut microbiota and resistome. *Curr Opin Microbiol* 27:51–56. <https://doi.org/10.1016/j.mib.2015.07.007>.
 39. van Schaik W. 2015. The human gut resistome. *Philos Trans R Soc Lond B Biol Sci* 370:20140087. <https://doi.org/10.1098/rstb.2014.0087>.
 40. Duranti S, Milani C, Lugli GA, Mancabelli L, Turrone F, Ferrario C, Mangifesta M, Viappiani A, Sanchez B, Margolles A, van Sinderen D, Ventura M. 2016. Evaluation of genetic diversity among strains of the human gut commensal *Bifidobacterium adolescentis*. *Sci Rep* 6:23971. <https://doi.org/10.1038/srep23971>.
 41. Duranti S, Milani C, Lugli GA, Turrone F, Mancabelli L, Sanchez B, Ferrario C, Viappiani A, Mangifesta M, Mancino W, Gueimonde M, Margolles A, van Sinderen D, Ventura M. 2015. Insights from genomes of representatives of the human gut commensal *Bifidobacterium bifidum*. *Environ Microbiol* 17:2515–2531. <https://doi.org/10.1111/1462-2920.12743>.
 42. Bottacini F, O'Connell Motherway M, Kuczynski J, O'Connell KJ, Serafini F, Duranti S, Milani C, Turrone F, Lugli GA, Zomer A, Zhurina D, Riedel C, Ventura M, van Sinderen D. 2014. Comparative genomics of the *Bifidobacterium breve* taxon. *BMC Genomics* 15:170. <https://doi.org/10.1186/1471-2164-15-170>.
 43. O'Callaghan A, Bottacini F, O'Connell Motherway M, van Sinderen D. 2015. Pangenome analysis of *Bifidobacterium longum* and site-directed mutagenesis through by-pass of restriction-modification systems. *BMC Genomics* 16:832. <https://doi.org/10.1186/s12864-015-1968-4>.
 44. Milani C, Turrone F, Duranti S, Lugli GA, Mancabelli L, Ferrario C, van Sinderen D, Ventura M. 2015. Genomics of the genus *Bifidobacterium* reveals species-specific adaptation to the glycan-rich gut environment. *Appl Environ Microbiol* 82:980–991. <https://doi.org/10.1128/AEM.03500-15>.
 45. Zhao Y, Tang H, Ye Y. 2012. RAPSearch2: a fast and memory-efficient protein similarity search tool for next-generation sequencing data. *Bioinformatics* 28:125–126. <https://doi.org/10.1093/bioinformatics/btr595>.
 46. Lugli GA, Milani C, Mancabelli L, van Sinderen D, Ventura M. 2016. MEGAnnotator: a user-friendly pipeline for microbial genomes assembly and annotation. *FEMS Microbiol Lett* 363:fnw049. <https://doi.org/10.1093/femsle/fnw049>.
 47. Li H, Durbin R. 2009. Fast and accurate short read alignment with Burrows-Wheeler transform. *Bioinformatics* 25:1754–1760. <https://doi.org/10.1093/bioinformatics/btp324>.
 48. Li H, Handsaker B, Wysoker A, Fennell T, Ruan J, Homer N, Marth G, Abecasis G, Durbin R, 1000 Genome Project Data Processing Subgroup. 2009. The Sequence Alignment/Map format and SAMtools. *Bioinformatics* 25:2078–2079.
 49. Langmead B, Salzberg SL. 2012. Fast gapped-read alignment with Bowtie 2. *Nat Methods* 9:357–359. <https://doi.org/10.1038/nmeth.1923>.
 50. Anders S, Pyl PT, Huber W. 2015. HTSeq—a Python framework to work with high-throughput sequencing data. *Bioinformatics* 31:166–169. <https://doi.org/10.1093/bioinformatics/btu638>.
 51. International Organization for Standardization (ISO). 2010. Milk and milk products—determination of the minimal inhibitory concentration (MIC) of antibiotics applicable to bifidobacteria and non-enterococcal lactic acid bacteria (LAB). ISO 10932:2010 (IDF 223:2010). ISO, Geneva, Switzerland.